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ABSTRACT: 
Background: Cinnamon is a rich botanical source of polyphenols, whose positive effects on 
blood lipid concentrations have been hypothesized, but have not been conclusively studied.  
Objective: To systematically review and evaluate the effect of administration of cinnamon on 
blood lipid concentrations. 
Methods: We assessed 13 RCTs with 750 participants investigating the effect of cinnamon 
supplementation on blood lipid concentrations. A meta-analysis was performed using random-
effect models, with weighted mean differences (with 95% CI) for endpoints calculated using a 
random-effects model. 
Results:  No statistically significant effect of cinnamon was observed on blood LDL-C (WMD: -
0.16 mmol/L [-6.19 mg/dL], 95% CI: -0.35, 0.03 [-13.53, 1.16], p = 0.10) and HDL-C (WMD: 
0.05 mmol/L [1.92 mg/dL], 95% CI: -0.03, 0.12 [-0.03, 4.64], p = 0.21) concentrations. 
However, a statistically significant reduction in blood triglycerides (WMD: -0.27 mmol/L [-
23.91 mg/dL], 95% CI: -0.39, -0.14 [-34.54, -12.40], p < 0.01) and total cholesterol 
concentrations (WMD: -0.36 mmol/L [-13.92 mg/dL], 95% CI: -0.63, -0.09 [-24.36, -3.48], p < 
0.01) was observed. HDL-C was significantly elevated following the omission of one study 
(WMD: 0.04 mmol/L [1.54 mg/dL], 95% CI: 0.03, 0.06 [1.16, 2.32], p < 0.01) during our 
sensitivity analysis. A meta-regression analysis was conducted and no significant association was 
found between changes in lipid parameters and cinnamon dose. In contrast, changes in blood 
levels of total cholesterol (slope: 0.09; 95% CI: 0.02, 0.16; p < 0.01), LDL-C (slope: 0.05; 95% 
CI: 0.001, 0.10; p = 0.05) and triglycerides (slope: 0.06; 95% CI: 0.04, 0.09; p < 0.01) were 
significantly and positively associated with the duration of supplementation. No statistically 
significant association was found between blood HDL-C changes and duration of 
supplementation.  
Conclusion: Cinnamon supplementation significantly reduced blood triglycerides and total 
cholesterol concentrations without any significant effect on LDL-C and HDL-C.  
 
Keywords: Cinnamon, cholesterol, triglycerides, lipid profiles, nutraceuticals. 
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INTRODUCTION 
It is well known in current medical practice that blood lipids are associated with coronary 
heart disease, and that their blood levels are good indicators of cardiovascular risk and good 
predictors of coronary disease outcome [1]. Considering the association between blood lipid 
concentrations and cardiovascular disease, organic compounds like herbal polyphenols and other 
natural substances found in different plants may be potential adjuvants in the treatment of 
various cardiovascular pathologies, and are being intensely studied [2]. In this regard, spices 
such as cinnamon are important because they are inexpensive, safe, and available globally [3]. 
Research into herbs and spices is made especially important due to the fact that recently, the 
United States Food and Drug Administration (FDA) withdrew its approval for the combined use 
of a statin with extended-release niacin and extended-release fenofibric acid preparations for the 
treatment of various dyslipidemias [4]. The current limitation on effective combination therapy 
with statins enhances the importance of research into spices and other bioactives. 
Cinnamon is extracted from the inner bark of trees from the genus Cinnamomum and 
belongs to the Lauraceae family widely spread in Asia, Australia and South America [5]. It is 
largely consumed as a spice being considered harmless to ingest [6]. Due to its pharmacological 
benefits, such as antibacterial and antioxidant properties, cinnamon is a significant element of the 
Chinese medicine [7]. The genus Cinnamomum contains two main species, Cinnamomum 
zeylanicum and Cinnamomum cassia, which has proven favorable antitumoral and antioxidant 
effects [8]. The main difference between these two varieties is their coumarin (1,2-benzopyrone) 
content [9]. Otherwise, both plant species possesses many active substances in different 
proportions, mainly eugenol (leaf), cinnamaldehyde (bark), and camphor (root) [10]. The 
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antioxidant phenolic constituents of cinnamon extracts have been suggested to diminish 
oxidative stress, bear anti-inflammatory properties, and improve cognitive function in animals 
[11]. As an important natural source of polyphenols, cinnamon has also been found to aid in the 
regulation of blood glucose in humans in the systematic review of randomized controlled trials 
[12], though the impact of cinnamon on blood lipids is still a controversial idea and the 
mechanism by which the cinnamon supplements potentially influence the level of blood lipids 
needs more clarification. 
Accordingly, this meta-analysis reviewed a number of different randomized, placebo-
controlled clinical trials, evaluating the effect of cinnamon on blood lipid concentration, 
specifically on different fractions of cholesterol and triglycerides, as they are important 
cardiovascular risk factors. 
 
METHODS  
Search Strategy 
This study was designed according to the guidelines of the 2009 preferred reporting items 
for systematic reviews and meta-analysis (PRISMA) statement. A systematic literature search 
was performed in SCOPUS, Embase and Medline databases. The search terms (in titles and 
abstracts) were: (randomized controlled trials OR RCT OR randomized OR lipid OR total 
cholesterol OR LDL-cholesterol OR HDL-cholesterol OR triglycerides) and (cinnamon). The 
wild-card term ‘‘*’’ was used to increase the sensitivity of the search strategy. The search was 
not limited to articles published in any specific language. The literature was searched from 
inception to date 31 July 2015.  
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Study Selection 
The following criteria was used to identify eligible studies: (i) Randomized placebo 
controlled trials with either a simple or cross-over design, (ii) investigation of the effects of any 
cinnamon species (Genus cinnamomum) or standardized cinnamon-enriched extracts on blood 
lipid concentrations, (iii) providing sufficient information on baseline and end-trial blood lipid 
concentrations in both cinnamon and control groups. Exclusion criteria were (i) animal and 
observational studies, (ii) uncontrolled studies, iii) administration of non-standardized extracts or 
extracts containing negligible amounts of cinnamon resulting in a daily intake of < 5 mg, and (iv) 
lack of sufficient information on baseline or end-trial lipid concentrations. In case of the latter 
item, authors of the article(s) were contacted and requested to provide numerical data. 
A systematic assessment of bias in the included studies was performed using the Cochrane 
criteria [13].  
 
Quantitative Data Synthesis 
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software 
(Biostat, NJ) [14]. All values were collated as in mmol/L and mg/dL. Standard deviations (SDs) 
of the mean difference were calculated using the following formula: SD = square root [(SDpre-
treatment)2 + (SDpost-treatment)2 – (2R × SDpre-treatment × SDpost-treatment)], assuming a correlation 
coefficient (R) = 0.5. If the outcome measures were reported in median and range (or 95% 
confidence interval [CI]), mean and standard SD values were estimated using the method 
described by Wan et al. Where standard error of the mean (SEM) was only reported, standard 
deviation (SD) was estimated using the following formula: SD = SEM × sqrt (n), where n is the 
number of subjects. 
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Net changes in measurements (change scores) for the trials were calculated using the 
following formula: (measure at the end of follow-up in the treatment group − measure at baseline 
in the treatment group) − (measure at the end of follow-up in the control group − measure at 
baseline in the control group). A random-effects model (using DerSimonian-Laird method) and 
the generic inverse variance method were used to compensate for the heterogeneity of studies in 
terms of study design, treatment duration, and the characteristics of populations being studied. 
Inter-study heterogeneity was assessed using Cochran Q test and I2 index. In order to evaluate 
the influence of each study on the overall effect size, sensitivity analysis was conducted using 
leave-one-out method, i.e. iteratively removing one study each time and repeating the analysis. 
Effect sizes were expressed as weighted mean difference (WMD) and 95%CI. 
 
Meta-regression 
A weighted random-effects meta-regression using unrestricted maximum likelihood model 
was performed to assess the association between the overall estimate of effect size with potential 
moderator variables including dose and duration of supplementation with cinnamon. 
 
Publication bias 
Potential publication bias was explored using visual inspection of Begg’s funnel plot 
asymmetry, Egger’s weighted regression, and “fail safe N” tests. Duval & Tweedie “trim and 
fill” method was used to adjust the analysis for the effects of publication bias.  
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RESULTS 
Flow and characteristics of included studies 
The initial screening for potential relevance removed the articles in whose titles and/or 
abstracts were obviously irrelevant (Figure 1). After assessment, 13 RCTs achieved the 
inclusion criteria and were preferred for the final meta-analysis.  
 
Characteristics of included studies 
 In total, 750 participants were randomized, of whom 388 were allocated to cinnamon 
supplementation groups and 362 to control groups in the 13 selected studies [15-27]. The number 
of participants in these trials ranged from 17 to 137. Included studies were published between 
2003 and 2015, and were conducted in China, Germany, Iran (n = 3), Netherlands, Pakistan, 
Sweden, Taiwan, Thailand, the United Kingdom, and the United States of America (n = 2). The 
following cinnamon supplementation was administered in the included trials: Between 1g and 6g 
of cinnamon powder per day in different trials (as noted in Table 1), 500mg of spray-dried water 
extract of cinnamon containing more than 4% type A procyanidins, and 1g Cinnulin PF® 
equivalent to 20g ground cinnamon per day. The duration of supplementation with cinnamon or 
its extracts ranged between 60 days and 4 months. All thirteen studies were designed as parallel-
group trials. Table 1 shows the demographic characteristics and baseline parameters of the 
included studies. 
 
Effect of cinnamon supplementation on blood lipid concentrations 
 Overall, the impact of cinnamon supplementation on blood concentrations of total 
cholesterol, LDL-C, HDL-C and triglycerides was assessed in 16, 16, 13 and 16 treatment arms, 
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respectively. No significant effect of cinnamon was observed on blood LDL-C (WMD: -0.16 
mmol/L [-6.19 mg/dL], 95% CI: -0.35, 0.03 [-13.53, 1.16], p = 0.10; Figure 2) and HDL-C 
(WMD: 0.05 mmol/L [1.92 mg/dL], 95% CI: -0.03, 0.12 [-0.03, 4.64], p = 0.21; Figure 3) 
concentrations. However, a significant reduction in blood triglycerides (WMD: -0.27 mmol/L [-
23.91 mg/dL], 95% CI: -0.39, -0.14 [-34.54, -12.40], p < 0.01; Figure 4) and total cholesterol 
concentrations (WMD: -0.36 mmol/L [-13.92 mg/dL], 95% CI: -0.63, -0.09 [-24.36, -3.48], p < 
0.01; Figure 5) was observed. All these effects were robust in sensitivity analysis (Figures 2, 4, 
5), apart from a significant elevation of blood HDL-C concentration following omission of one 
study [22] from meta-analysis (WMD: 0.04 mmol/L [1.54 mg/dL], 95% CI: 0.03, 0.06 [1.16, 
2.32], p < 0.01; Figure 3). 
 
Meta-regression 
Meta-regression analysis was conducted to evaluate the association between changes in 
blood lipid concentrations and potential confounders including dose and duration of 
supplementation with cinnamon. No significant association was found between changes in lipid 
parameters and cinnamon dose (Figure 6). In contrast, the difference in mean blood values of 
total cholesterol (slope: 0.09; 95% CI: 0.02, 0.16; p < 0.01), LDL-C (slope: 0.05; 95% CI: 0.001, 
0.10; p = 0.05) and triglycerides (slope: 0.06; 95% CI: 0.04, 0.09; p < 0.01), between those 
receiving cinnamon and controls, were significantly and positively associated with the duration 
of supplementation (Figure 7). It means that longer duration of supplementation was correlated 
with an smaller effect size of cinnamon on its reduction of total cholesterol, LDL-C, and 
triglycerides. No significant association was found between blood HDL-C changes and duration 
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of supplementation (Figure 7).  
 
Publication bias 
Visual inspection of funnel plots suggested an asymmetry in the meta-analyses of 
cinnamon's effects on blood lipid concentrations. Using “trim and fill” method, 3, 5, 5 and 1 
potentially missing studies were imputed for the meta-analyses of total cholesterol, LDL-C, 
HDL-C and triglycerides (Figure 8). Corrected effect sizes (following imputation of potentially 
missing studies) and the results of Egger’s linear regression, Begg’s rank correlation, and “fail 
safe N” tests are summarized in Table 3. 
 
DISCUSSION 
Dietary supplements, as a whole, can potentially provide us with a rich source of relatively 
inexpensive, safe, and healthy adjuvants to medicinal therapy for a wide range of diseases. If 
such products are tested and proven to be useful, it would bring a great benefit to the population 
by reducing the total number of medicines required by the patient, and by supplementing 
vitamins and other nutrients that these patients might be lacking. Furthermore, they could help 
reduce medication side-effects, including those that are psychogenic (i.e. nocebo effect) [28, 29], 
and limit their associated residual risks by reducing the need to increase medication dose if 
patient response is low or moderate [30]. In the case of statins, the dose is sometimes increased if 
the patient's total blood cholesterol remains unacceptably elevated, increasing the risk of statin 
intolerance [31, 32]. Cinnamon could curb this risk by potentially helping lower total blood 
cholesterol, reducing the need to increase Statin dose by as much. Other supplements have also 
shown similar promising results [33], such as spirulina for its effects on blood cholesterol [34] 
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and astaxanthin for its effects on blood glucose [35], which further accentuates the need to 
expand research in the field. 
This meta-analysis aimed to determine whether cinnamon supplementation has the potential 
to be used as an adjuvant therapy for persons who are at a high risk for cardiovascular disease, 
by improving their blood lipid profile. This, and other studies like it, are very relevant and 
necessary, as on April 18th 2016, the United States Food and Drug Administration (FDA) 
withdrew its approval of the co-administration, with statins, of niacin extended-release tablets 
and fenofibric acid delayed-release capsules, in the treatment of multiple dyslipidemias, for their 
inability to show an improvement in morbidity and mortality over their individual monotherapies 
[4]. Such news warrants more research into herbs, spices, and other supplements as potential 
replacements for niacin and fenofibric acid specifically, and in the treatment of other diseases in 
general. 
Our finding that cinnamon supplementation decreases blood triglycerides and total 
cholesterol contradicts the findings of another meta-analysis on this subject [36]. One possible 
explanation is that Baker et al. investigated only a handful of small studies, and might have 
lacked the power to detect statistically significant differences [36]. Another explanation might be 
that Baker et al. incorporated studies that specifically focused on patients with diabetes mellitus, 
a demographic that might be statistically different from the general population in this regard 
[36]. Previous meta-analysis, which only included diabetic patients (n=543), corroborates the 
findings of our study, finding statistically significant reductions in blood total cholesterol (-15.60 
mg/dL; 95% CI, -29.76 to -1.44 mg/dL) and triglycerides (-29.59 mg/dL; 95% CI, -48.27 to -
10.91 mg/dL), but also significant reduction of LDL-C (-9.42 mg/dL; 95% CI, -17.21 to -1.63 
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mg/dL) and an increase of HDL-C (1.66 mg/dL; 95% CI, 1.09 to 2.24 mg/dL) [37].  
There are some proposed mechanisms of action of cinnamon, which could help explain our 
findings. In regards to the decrease in blood triglyceride concentration, studies have shown that 
polyphenols found in cinnamon increase glycogen synthesis and decrease glycogenolysis  [12], 
decrease the absorption of glucose by the small intestine [38], and regulate peroxisome 
proliferator-activated receptor alpha (PPAR-α) and gamma-mediated metabolism [39], findings 
which are corroborated by other research [40]. In this way, the decrease in chylomicron 
absorption and possible increase in triglyceride uptake by adipocytes could explain our findings. 
The possible activation of PPAR-α receptors by cinnamon could help explain the reduction in 
blood cholesterol [41]. Another possible explanation might be that the vitamin content might be 
responsible for an increased lipid metabolism [5].  
In regards to the safety of cinnamon supplementation, the European Food Safety Authority 
(EFSA) states that a prudent Tolerable Daily Intake (TDI) for coumarin is 0.1mg/kg body 
weight/day [42]. One study that tested 60 samples of ground cinnamon, obtained in the Czech 
Republic from normal supermarkets, found that the averages of their samples contained 
coumarin in a range from 2650 to 7017mg/kg [43]. As such, for an adult male that weighs 70 kg, 
an average of 1g – 2.6g of ground cinnamon per day, depending on the source and type of 
cinnamon, would be sufficient to reach the EFSA's TDI limit. A 2012 systematic review and 
meta-analysis described the safety of C. zeylancium (i.e. ‘true’ cinnamon) on rats with 
streptozocin-induced diabetes by evaluating 4 animal studies [39]. They calculated the equivalent 
human LD50 (median lethal dose) of C. zeylancium to be 11.4 ± 0.2g/kg, which would be almost 
800g for the average 70kg male. For comparison, the highest single dose given to any subject in 
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the studies we evaluated was the equivalent of 10g of cinnamon (with an average of 
approximately 2g per dose across all studies) although the species of Cinnamomum administered 
did differ across studies. The aforementioned meta-analysis also discussed a study where rats 
exposed to doses of cinnamon up to 20x higher than their target therapeutic dose displayed no 
change in behavior across the 3 weeks that they were studied, nor did they exhibit any 
statistically significant blood elevations in liver enzymes. However, significant elevations of 
blood urea and uric acid were found at therapeutic doses in two of the studies [39]. Of concern is 
a case report, which details a patient presenting with acute hepatitis after concomitantly taking 
rosuvastatin 40mg and cinnamon supplements for some undisclosed period of time. However the 
authors did not present which supplement and in what dose it was taken [44]. Unfortunately, no 
animal or human studies evaluating the long-term safety of cinnamon administration are 
available, and none of the studies we evaluated mentioned their subjects receiving statin therapy 
during the trial. More research is necessary before long-term cinnamon administration, especially 
alongside statins, can be considered safe. 
One of the main limitations of our meta-analysis is the fact that most of the studies done on 
the lipid-lowering effects of cinnamon were performed on diabetic patients. As a result, 12 out of 
the 13 studies were strictly conducted on patients with diabetes mellitus or impaired glucose 
tolerance. The presence of diabetes may be a confounding factor, and make extrapolating the 
results of this study to the general population difficult without further research. More research 
needs to be done to elucidate whether cinnamon is effective in non-diabetic patients. Another 
limitation is the heterogeneity of the cinnamon species examined in the individual studies. Some 
studies used Cinnamomum cassia extracts, while others used C. loureiroi, C. Aromaticum, 
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combinations of these species, or did not specify the species. It is yet unclear whether or not 
these differences may impact the presence and/or concentrations of the substances in cinnamon 
responsible for the possible effects observed in this meta-analysis. More research needs to be 
done focusing on individual cinnamon species in order to determine whether this impacts our 
observations. Finally, among the 13 studies analyzed, only 2 explicitly excluded patients taking 
lipid-lowering medication [17, 27], and 3 more (which focused on diabetic patients) mentioned 
which medications the patients were taking, but did not specifically mention the presence or 
absence of lipid-lowering medications [20, 23, 25]. Among the rest, either some patients were on 
statins and/or other lipid-lowering medications, or medications were not mentioned altogether. 
While not certain, these differences might serve as a source of bias in our results. 
In conclusion, cinnamon supplementation significantly reduced blood triglycerides and total 
cholesterol concentrations but had no effects on blood LDL-C and HDL-C concentrations. These 
results indicate that cinnamon supplementation may be of marginal benefit to diabetic patients 
and patients with impaired glucose tolerance, especially with atherogenic dyslipidemias. More 
research is necessary to elucidate whether these findings are also clinically significant. 
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FIGURES LEGEND:  
Figure 1. Flow chart of the number of studies identified and included into the meta-analysis.   
Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of cinnamon supplementation on blood LDL-cholesterol concentrations. Lower plot 
shows leave-one-out sensitivity analysis. 
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Figure 3. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of cinnamon supplementation on blood HDL-cholesterol concentrations. Lower plot 
shows leave-one-out sensitivity analysis. 
Figure 4. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of cinnamon supplementation on blood triglycerides concentrations. Lower plot shows 
leave-one-out sensitivity analysis. 
Figure 5. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of cinnamon supplementation on blood total cholesterol concentrations. Lower plot 
shows leave-one-out sensitivity analysis. 
Figure 6. Random-effects meta-regression plots of the association between mean changes in 
blood concentrations of lipids and dose of cinnamon. 
Figure 7. Random-effects meta-regression plots of the association between mean changes in 
blood concentrations of lipids and duration of supplementation with cinnamon. 
Figure 8. Funnel plot displaying publication bias in the studies reporting the impact of cinnamon 
supplementation on blood concentrations of lipids. 
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Table 1. Demographic characteristics of the included studies. All values for BMI, blood pressure, and plasma lipids are baselines. 
 
 
Cinna
mon 
supple
mentat
ion 
Akilen et al. 
(19) 
Anderson et al. 
(20) 
Askari et al. 
(21) 
Blevins et al. (22) Khan et 
al.(23) 
Lu et al. (24) Mang et 
al.(25) 
Sengsuk et 
al.(26) 
Vafa et 
al.(27) 
Vanschoonbeek et 
al.(28) 
Wickenberg 
et al.(29) 
Zahmatkesh 
et al.(30) 
Ziegenfuss 
et al.(31) 
Year 2010 2015 2013 2007 2003 2012 2006 2015 2012 2006 2014 2014 2006 
Location UK Taiwan Iran USA Pakistan China Germany Thailand Iran Netherlands Sweden Iran USA 
Study design  Randomized, 
placebo-controlled, 
double-blind 
clinical trial with 
two parallel groups 
Randomized 
double-blind 
placebo 
controlled 
parallel group 
trial 
Randomized 
double 
blinded, 
placebo 
controlled trial 
with two 
parallel 
groups 
Randomized 
double-blind 
placebo-controlled 
parallel trial 
Randomized, 
double-blind, 
placebo 
controlled, 
parallel 
clinical trial 
Randomized, 
double-blind, 
placebo-
controlled 
parallel trial 
Randomized, 
double-blind 
placebo-
controlled 
parallel trial 
Randomized 
double-blind 
placebo-
controlled 
parallel trial 
Randomized 
double-blind 
placebo-
controlled 
parallel trial 
Randomized 
Double-blind 
placebo-controlled 
parallel trial 
Randomized 
double-blind 
placebo-
controlled 
parallel trial 
Randomized 
Double-blind, 
randomized 
controlled trial 
Randomized, 
double-blind, 
placebo 
controlled 
parallel trial 
Duration of 
trial 
 12 weeks 2 months 12 weeks 3 months 60 days 3 months 4 months 60 days 8 weeks 6 weeks 12 weeks 8 weeks 12 weeks 
Type and dose 
of cinnamon 
supplements 
 2 g cinnamon 
capsules 
spray-dried water 
extract of 
cinnamon 
containing more 
than 4% type A 
procyanidins 
polyphenols, in 
250 mg capsules, 
twice a day 
1.5 g 
cinnamon 
capsules 
1 g cinnamon 
capsules 
1g cinnamon 
capsulesA 
 
3g cinnamon 
capsulesB 
 
6g cinnamon 
capsulesC 
60 mg 
cinnamon 
tablets given 
as: 
Low Dose = 2 
Tab/d 
(120mg total) 
High Dose = 6 
Tab/d 
(360 mg total) 
3 x 112 mg 
aqueous 
cinnamon 
extract / day 
112 mg 
aqueous 
extract 
corresponds to 
1g of 
cinnamon 
500 mg 
cinnamon 
capsules  
 1 capsule 3x  
/ day 
(1500 mg 
total) 
500 mg 
cinnamon 
capsules 
2 capsules 3x 
/ day 
(3000 mg 
total) 
500 mg cinnamon 
capsules 
1 capsule 3x / day 
(1500 mg total) 
700 mg 
capsules 
containing 
500mg C. 
cassia + 200 
mg cellulose 
1 capsule 2x / 
day 
(1000 mg 
total) 
500 mg 
cinnamon 
capsules 
2 capsules 2x / 
day 
(2000mg total) 
250 mg 
capsules 
Cinnulin PF®, 
equivalent to 
5g ground 
cinnamon. 
2 capsules 2x / 
day 
(1000 mg 
total)  
 
Participants YES 30 64 23 30 10A 23LD 33 49 19 12 9 31 12 
10B 23HD 
10C 
NO 28 73 22 28 10D 20 32 50 18 13 8 30 10 
10E 
10F 
Age (years) YES 54.90 ±10.14 NS NS 63.6 52.0± 5.85 62.4 ± 7.9LD 62.8 ± 8.37 57.3 ± 1.1 54.11 ± 10.37 62.0 ± 2.0 73 ± 2 56.8 ± 6.0  46.3 ± 8.8 
58.9 ± 6.4HD 
NO 54.43 ±12.53 NS NS 58.0 52.0± 6.87 60 ± 5.9 63.7 ± 7.17 56.9 ± 1.2 55.67 ± 7.98 64.0 ± 2.0 72 ±  2 53.1 ± 8.4 45.6 ± 11.1 
Female (%) YES 19 (63.4) NS NS 30 (51) 30 (50) 15 (65.2)LD 12 (36.4) 33 (67.3) 13 (68.4) 12 (100.0) 5 (55.6) (51) 4 (0.33) 
14 (60.9)HD 
NO 13 (46.4) NS NS 12 (60.0) 9 (28.1) 34 (68.0) 11 (61.1) 13 (100.0) 5 (62.5) (45) 7 (0.7) 
Male (%) YES 11 (36.6) NS NS 28 (49) 30 (50) 8 (34.8)LD 21 (63.6) 16 (32.7) 6 (31.6) 0 (0) 4 (44.4) (49) 8 (0.66) 
9 (39.1)HD 
8 (40.0) 23 (71.9) 16 (32.0) 7 (38.9) 0 (0) 3 (37.5) (55) 3 (0.3) 
NO 15 (53.6) NS NS 
BMI (kg/m2) YES 33.36 ±4.20 24.8 ± 0.4* 29. 9 ± 3. 9 
 
32.5± 1.7 
 
NSA NSLD 
 
29.6 ± 4.64 24.7 (22.1-
27.4)** 
29.23 ± 3.98 30.7 ± 1.1 25.7 ± 1.3 NS 32.3 ± 5.7 
NSB 
NSC NSHD 
NO 32.13 ± 8.31 25.8 ± 0.3* 30. 3 ± 4. 1 32.0±1.5 NSD NS 30.1 ± 5.22 24.7 (22.5- 28.59 ± 3.54 30.1 ± 1.4 28.6 ± 1.9 NS 34.4 ± 12.6 
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NSE 27.4)** 
NSF 
Total 
cholesterol 
mmol/l 
(mg/dL) 
YES 4.31 ± 1.07 
(166.67 ± 41.38) 
 
5.20 ± 0.14* 
(201.08 ± 5.41) 
4.32 ± 1.53 
(167.05 ± 
59.17) 
 
4.40 ± 0.21 
(170.15 ± 8.12) 
4.09 ± 0.30 A 
(158.16 ± 
11.60) 
4.96 ± 1.35LD 
(191.80 ± 
52.20) 
5.29 ± 0.89 
(204.56 ± 
34.42) 
4.26 (3.56-
4.77)** 
 
(164.76 
(137.67-
184.46)) 
4.38 ± 0.85 
(169.37 ± 
32.87) 
5.05 ± 0.15 
(195.28 ± 5.80) 
4.9 ± 0.4* 
(189.48 ± 
15.47) 
5.85 ± 1.28 
(226.22 ± 
49.50) 
4.78 ± 1.14 
(184.84 ± 
44.08) 
4.03 ± 0.34 B 
(155.84 ± 
13.15) 
5.18 ± 0.78HD 
(200.31 ± 
30.16) 
4.86 ± 0.19 C 
(187.64 ± 
7.35) 
NO 4.10 ± 0.87 
(158.55 ± 33.64) 
 
 
5.12 ± 0.12* 
(197.99 ± 4.64) 
 
4.84 ± 0.55 
(187.16 ± 
21.27) 
 
4.56 ± 0.21 
176.34 ± 8.12) 
 
4.78 ± 0.31D 
(184.84 ± 
11.99) 
4.60 ± 1.04 
(177.88 ± 
40.22) 
5.17 ± 0.75 
(199.92 ± 
29.00) 
4.39 (3.79-
5.02)** 
 
(169.76 
(146.56-
194.12)) 
 
4.02 ± 0.91 
(155.45 ± 
35.19) 
4.91 ± 0.30 
(189.87 ± 11.6) 
4.5 ± 0.2* 
(174.02 ± 
7.73) 
5.66 ± 0.78 
(218.87 ± 
30.16) 
4.97 ± 1.27 
(192.19 ± 
49.11) 
4.94 ± 0.35E 
(191.03 ± 
13.53) 
5.84 ± 0.42F 
(225.83 ± 
16.24) 
LDL-C  
mmol/l 
(mg/dL) 
 
YES 2.47 ± 0.96 
(95.51 ± 37.12) 
 
3.48 ± 0.14* 
(134.57 ± 5.41) 
 
1.93 ± 1.69 
(74.63 ± 
65.35) 
 
2.62 ± 0.17 
(101.32 ± 6.57) 
2.35 ± 0.13A 
(90.87 ± 5.03) 
2.65 ± 0.76LD 
(102.48 ± 
29.39) 
3.48 ± 0.71 
(134.57 ± 
27.46) 
2.19 (1.63-
2.61)** 
 
(84.69 (63.03-
100.93)) 
2.44 ± 0.77 
(94.35 ± 
29.78) 
3.06 ± 0.15 
118.33 ± 5.80) 
3.2 ± 0.4* 
(123.74 ± 
15.47) 
3.44 ± 0.92 
(113.02 ± 
35.58) 
2.77 ± 0.93 
(107.12 ± 
35.96) 
1.97 ± 0.18B 
(76.18 ± 6.96) 
3.14 ± 0.6HD 
(121.43 ± 
23.20) 2.72 ± 0.11C 
(105.18 ± 
4.15) 
NO 2.27 ± 0.75 
(87.78 ± 29.00) 
 
3.45 ± 0.09* 
(133.41 ± 3.48) 
 
2.47 ± 0.59 
(95.51 ± 
22.82) 
 
2.72 ± 0.17 
(105.18 ± 6.57) 
 
2.40 ± 0.22D 
(92.81 ± 8.51) 
2.70 ± 0.86 
(104.41 ± 
33.26) 
3.59 ± 0.69 
(138.83 ± 
26.68) 
2.32 (1.86-
2.83)** 
 
(89.71 (71.93-
109.44)) 
2.39 ± 0.84 
(92.42 ± 
32.48) 
3.04 ± 0.25 
(117.56 ± 9.67) 
2.7 ± 0.2* 
104.41 ± 7.73) 
3.43 ± 0.72 
(132.64 ± 
27.84) 
2.72 ± 1.34 
(105.18 ± 
51.82) 2.79 ± 0.27E 
(107.89 ± 
10.44) 
3.36 ± 0.37F 
(129.93 ± 
14.31) 
HDL-C  
mmol/l 
(mg/dL) 
YES 1.18 ± 0.29 
(45.63 ± 11.21) 
 
1.26 ± 0.04* 
(48.72 ± 1.55) 
 
1.19 ± 0.21 
(46.02 ± 8.12) 
 
1.14 ± 0.04 
(44.08 ± 1.55) 
 
NSA 1.23 ± 0.36LD 
(47.56 ± 
13.92) 
1.44 ± 0.49 
(55.68 ± 
18.95) 
1.22 (1.01-
1.44)** 
 
(47.18 (39.06-
55.68)) 
1.12 ± 0.11 
(43.31 ± 4.25) 
1.42 ± 0.09 
(54.91 ± 3.48) 
1.4 ± 0.1* 
(54.14 ± 3.87) 
0.98 ± 0.15 
(37.90 ± 5.80) 
1.29 ± 0.34 
(49.88 ± 
13.15) 
NSB 1.56 ± 0.49HD 
(60.33 ± 
18.95) 
NSC 
NO 1.16 ± 0.19 
(44.86 ± 7.35) 
 
1.28 ± 0.04* 
(49.50 ± 1.55) 
1.09 ± 0.16 
(42.15 ± 6.19) 
 
NS*** 
 
NSD 1.43 ± 0.50 
55.30 ± 19.34) 
1.34 ± 0.31 
(51.82 ± 
11.99) 
1.42 (1.15-
1.67)** 
 
(54.91 (44.47-
64.58)) 
1.06 ± 0.14 
(40.99 ± 5.41) 
1.29 ± 0.11 
49.88 ± 4.25) 
1.5 ± 0.1* 
(58.01 ± 3.87) 
0.99 ± 0.12 
(38.28 ± 4.64) 
1.42 ± 0.36 
(54.91 ± 
13.92) NSE 
NSF 
Triglycerides 
mmol/l 
(mg/dL) 
 
YES 1.65 ± 0.93 
(146.14 ± 82.37) 
 
2.20 ± 0.21* 
(194.85 ± 18.60)  
 
2.52 ± 1.0 
(223.20 ± 
88.57) 
1.49 ± 0.18 
(131.97 ± 15.94) 
1.67 ± 0.21A 
(147.91 ± 
18.60) 
2.93 ± 2.08LD 
(259.51 ± 
184.23) 
1.96 ± 1.65 
(173.60 ± 
146.14) 
  
1.32 (1.02-
2.27)** 
 
(116.91 
(90.34-
201.05) 
1.84 ± 0.59 
(162.97 ± 
52.26) 
1.1 ± 0.1 
(97.43 ± 8.86) 
1.1 ± 0.1* 
(97.43 ± 8.86) 
3.06 ± 0.56 
(271.02 ± 
49.60) 
1.87 ± 1.60 
(185.63 ± 
141.71) 
2.16 ± 0.52B 
(191.31 ± 
46.06) 
1.74 ± 1.05HD 
(154.11 ± 
93.00) 
2.07 ± 0.32C 
(183.34 ± 
28.34) 
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NO 1.48 ± 1.04  
(131.08 ± 92.11) 
 
2.05 ± 0.17* 
(181.57 ± 15.06) 
 
2.43 ± 0.94 
(215.23 ± 
83.26) 
 
1.76 ± 0.26 
(155.88 ± 23.03) 
 
2.45 ± 0.32D 
(217.00 ± 
28.34) 
1.68 ± 0.67 
(148.80 ± 
59.34) 
1.66 ± 0.78 
(147.03 ± 
69.08) 
1.40 (1.01-
2.28)** 
 
(124.00 
(89.46-
201.94) 
1.53 ± 0.46 
(135.51 ± 
40.74) 
1.1 ± 0.1 
(97.43 ± 8.86) 
1.1 ± 0.1* 
(97.43 ± 8.86) 
2.47 ± 0.34 
(218.77 ± 
30.11) 
1.86 ± 1.21 
(164.74 ± 
107.17) 
2.21 ± 0.29E 
(195.74 ± 
25.69) 
2.65 ± 0.35F 
(234.71 ± 
31.00) 
SBP (mmHg) YES 133 ± 8.6  
 
128.3 ± 1.9* NS NS NSA NSLD NS 134.5 (126.8-
144.0)** 
123.42 ± 11.9 NS 140.5 ± 4.7* NS 133 ± 14 
NSB NSHD 
NSC 
NO 134 ± 10.9  
 
122.7 ± 1.5* NS NS NSD NS NS 135.0 (127.0-
142.0)** 
125.56 ± 
11.49 
NS 122 ± 16.7* NS 133 ± 22 
NSE 
NSF 
DBP (mmHg) YES 85 ± 6.45 
 
78.2 ± 1.1* NS NS NSA NSLD NS 83.5 (79.0-
91.3)** 
80.0 ± 6.87 NS 82.0 ± 2.8* NS 83 ± 6 
NSB NSHD 
NSC 
NO 87 ± 8.82 
 
75.9 ± 0.9* NS NS NSD NS NS 80.0 (73.5-
90.0)** 
80.56 ± 6.39 NS 80.0 ± 2.6* NS 83 ± 14 
NSE 
NSF 
Values are generally expressed as mean ± SD, except: 
* – Mean ± Standard Error of the Mean 
** – Median (Interquartile Range) 
 
ABBREVIATIONS: 
A  = Group receiving 1g cinnamon / day B = Group receiving 3g cinnamon / day C = Group receiving 6g cinnamon / day D = Group receiving placebo corresponding to 
group A in number of tablets given 
E = Group receiving placebo corresponding to 
group B in number of tablets given 
F = Group receiving placebo corresponding to 
group C  in number of tablets given 
BMI = Body-mass index DBP = Diastolic blood pressure 
HD = High dose HDL-C = High-density lipoprotein cholesterol 
 
LD = Low dose LDL-C = Low-density Lipoprotein Cholesterol 
NS = Not specified SBP = Systolic blood pressure 
 
*** Paper and electronic sources for this study 
list value incorrectly. 
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Table 2. Risk of bias assessment of the studies included in this meta-analysis 
 
Study SEQUENCE 
GENERATION 
ALLOCATION 
CONCEALMENT 
BLINDING OF 
PARTICIPANTS 
AND 
PERSONNEL 
BLINDING OF 
OUTCOME 
ASSESSMENT 
INCOMPLETE 
OUTCOME 
DATA 
SELECTIVE 
OUTCOME 
REPORTING 
OTHER 
POTENTIAL 
THREATS 
TO 
VALIDITY 
Akilen et al. 
2010 
L L L L L L L 
Anderson et al. 
2015 
U L L U L L L 
Askari et al. 
2014 
L L L L L L L 
Blevins et al. 
2007 
U L L L L L L 
Khan et al. 
2003 
L L U U L L L 
Lu et al. 2012 U L L U L L L 
Mang et al. 
2006 
U U L U L L L 
Sengsuk et al. 
2015 
L L L L L L L 
Vafa et al. 2012 U U L L L L L 
Vanschoonbeek 
et al. 2006 
U U L U L L L 
Wichenberg et 
al. 2014 
L L L U L L L 
Zahmatkash et 
al. 2014 
U U L U L L U 
Ziegenfuss et 
al. 2006 
U U L U L L L 
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Table 3. Assessment of publication bias in the meta-analysis cinnamon’s effects on plasma lipid concentrations of lipids 
 Corrected effect sizea Begg’s rank correlation test, Egger's linear regression test Fail safe N test 
WMD 95% CI Kendall’s Taua z-value p-value Intercept 95% CI p-value nb 
Total cholesterol -0.46 -0.77, -0.16 0.19 1.04 0.300 -2.31 -5.09, 0.47 0.096 243 
LDL-C -0.27 -0.47, -0.07 0.14 0.77 0.444 -1.32 -3.89, 1.25 0.289 61 
HDL-C 0.08 0.02, 0.15 0.42 2.01 0.044 -0.10 -2.53, 2.34 0.933 85 
Triglycerides -0.26 -0.38, -0.14 0.04 0.23 0.822 -1.12 -2.34, 0.10 0.069 151 
aWith continuity correction; bNumber of theoretically missing studies to bring the p-value to > 0.05. 
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The Effects of Cinnamon Supplementation on Plasma Lipid Concentrations: A Systematic 
Review and Meta-Analysis  -- Highlights 
• Cinnamon supplementation reduced total plasma cholesterol and triglycerides. 
• Effect is correlated with duration of treatment, but not with dose administered. 
• HDL was also significantly increased after removing one study from the analysis. 
